DEERFIELD, Ill., January 9, 2012 - Baxter International Inc.
(NYSE:BAX) announced today that Jean-Luc Butel has been appointed
corporate vice president and president, international, reporting to
Robert L. Parkinson, Jr., chairman and chief executive officer. He
will assume his new role on February 20, 2012.
Butel, 55, will be responsible for leading the company's
international operations. Most recently, Butel was Executive
Vice President and Group President, International, at
Medtronic.
"Geographic expansion continues to be a key growth driver for
Baxter. Our global presence and the strength of our country
and regional organizations position us to meet the ever increasing
demand for healthcare worldwide, particularly for the medically
necessary products that we provide," said Robert L. Parkinson,
Jr., chairman and chief executive officer. "Jean-Luc brings
significant international expertise to Baxter, and he will be a
tremendous asset to the company in his new role leading our
international business."
Butel served in a variety of senior management positions at
Medtronic since 2003, including leading the company's international
business operations and the Asia Pacific region. Prior to
Medtronic, he spent 13 years with Johnson & Johnson in
roles of increasing responsibility, and eight years with Becton
Dickinson in leadership roles, including general manager of the
Microbiology business in Japan, president of Japan and president of
Worldwide Consumer Healthcare.
Butel received his B.A. in international affairs from George
Washington University, and his M.B.A. in international business
from the American School of International Management
(Thunderbird).
Baxter International Inc., through its subsidiaries, develops,
manufactures and markets products that save and sustain the lives
of people with hemophilia, immune disorders, infectious diseases,
kidney disease, trauma, and other chronic and acute medical
conditions. As a global, diversified healthcare company,
Baxter applies a unique combination of expertise in medical
devices, pharmaceuticals and biotechnology to create products that
advance patient care worldwide.
SOURCE